Correspondence 0001213900-24-033883 from ADIAL PHARMACEUTICALS, INC. (ADIL)
ADIAL PHARMACEUTICALS, INC.
Date: April 17, 2024 · CIK: 0001513525 · Accession: 0001213900-24-033883
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278652
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Lauren Hamill Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 12, 2024 File No: 333-278652
Dear Ms. Hamill:
Adial Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as amended (File No. 333-278652), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Friday, April 19, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
April 17, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Lauren Hamill
Re:
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 12, 2024
File No: 333-278652
Dear Ms. Hamill:
Adial Pharmaceuticals, Inc.
(the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3,
as amended (File No. 333-278652), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”)
to become effective on Friday, April 19, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Hank Gracin of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow
at (516) 457-4238, or Mr. Gracin at (561) 926-7995 with any questions you may have concerning this request, and please notify either of
them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
By:
/s/ Cary Claiborne
Name:
Cary Claiborne
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Hank Gracin, Blank Rome LLP